Monographie - Ceftolozane / tazobactam - Stabilis 4.0

Son güncelleme :
08/05/2024

Antibiyotik

Ceftolozane / tazobactam

Enjeksiyon

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

Pdf

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Zepilen	İspanya
Zerbaxa	Almanya, Amerika Birleşik Devletleri, Arjantin, Büyük Britanya, Ekvador, Fransa, İspanya, İsviçre, Meksika, Peru, Romanya, Şili

Kaynaklar

Enjeksiyon

Kaynaklar : Ceftolozane / tazobactam

	Tip	Yayın
3520	Laboratuar	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratuar	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratuar	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratuar	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3803	Laboratuar	Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics Laboratoires Merck Sharp & Dohme Chibret 2020
3827	Afiş	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Afiş	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Afiş	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3984	Dergi	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	Dergi	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Dergi	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4378	Dergi	Harmanjeet H, Jani H, Zaidi S.T.R, Wanandy T, Castelino R.L, Sud K, Peterson G.M, Patel R.P. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 2020 ; 40, 5: 470-476.
4434	Dergi	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Dergi	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	Dergi	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4645	Dergi	Jamieson C, Drummond F, Hill T, Ozolina L, Gilchrist M, Seaton R.A, Santillo M, Wilkinson A-S, Allwood M.C. Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist 2021
4801	Dergi	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales